ReviewGlycoconjugate journal2025
Cell cycle regulation in cancer cells by O-GlcNAcylation.
Review in Glycoconjugate journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.Molecular biomedicine · 2026Review
- A study on bile from patients with recurrent common bile duct stones and cholangiocarcinoma following ERCP using non-targeted metabolomics.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of death worldwide. Due to the multiple molecular mechanisms involved in cell transformation, its biology continues to be studied from different perspectives and in other research areas. A hallmark of cancer is its accelerated proliferation and overactivation of the cell cycle, caused by a dysregulated metabolism and the activation of different signaling pathways, such as the PI3/K-Akt pathway. On the other hand, the hexosamine biosynthetic pathway plays an essential role in producing UDP-GlcNAc, the primary substrate for O-GlcNAcylation. This non-canonical post-translational modification regulates protein stability, localization and interactions. This work aims to examine the role of the O-GlcNAcylation in regulating the cell cycle across diverse types of cancer and its involvement in the PI3/K-Akt pathway as a promoter of the cell cycle progression. Additionally, the study also proposes new alternatives for cancer diagnosis, prognosis, and treatment.
Indexed as
Identifiers
40824482What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.